人工关节感染一期术后抗生素间隔器留置的结局
该回顾性病例系列分析因假体周围感染行两阶段翻修一期放置活动性抗生素间隔器后未行二期翻修的33例患者,中位随访4-5年,2年无计划再手术或取出生存率89%,感染累积发生率5%,机械并发症累积发生率5%,患者生存率92%。
要点
- 保留间隔器者2年无再手术或取出生存率89%,感染累积发生率5%。
- 间隔器骨折或脱位累积发生率5%,需关注机械并发症风险。
- 部分患者功能下降,术前咨询应明确告知保留间隔器的风险。
核心结论
- 对于选择不进行二期翻修的患者,保留活动性抗生素间隔器可在部分患者中实现感染控制,但仍存在机械并发症和功能下降风险。
研究设计与样本
- 回顾性病例系列,纳入2011年3月至2023年7月因慢性假体周围感染行一期活动性间隔器置入的THA和TKA患者,最终分析13例THA和25例TKA,至少随访2年或至死亡。
主要发现
- 2年时,THA和TKA合并的无计划再手术或取出生存率为89%(95%CI 80%-99%),感染累积发生率为5%(95%CI 0%-12%),患者Kaplan-Meier生存率为92%(95%CI 84%-100%)。
- 机械并发症(间隔器骨折或脱位)累积发生率为5%(95%CI 0%-13%)。
- THA队列10例中,术前2例轮椅、2例助行器、1例拐杖、2例手杖、3例无辅助行走;末次随访时4例轮椅、2例助行器、2例手杖、2例无辅助行走。
- TKA队列25例中,术前2例轮椅、5例助行器、13例手杖、5例无辅助行走;末次随访时2例轮椅、5例助行器、13例手杖、5例无辅助行走。
临床怎么用
- 对于因患者偏好、医生偏好或医学原因无法行二期翻修的患者,可考虑保留活动性抗生素间隔器,但需告知机械并发症和功能下降风险。
局限性
- 回顾性设计,样本量小,仅纳入单中心患者,部分患者失访,未进行正式假设检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prolonged retention of antibiotic-loaded articulating spacers after the first stage of a two-stage revision for periprosthetic joint infection (PJI) can occur because of patient preference, surgeon preference, or medical reasons that prevent the planned second stage. Little is known about the frequency of persistent infections, mechanical complications, and functional results in patients with retained spacers. QUESTIONS/PURPOSES: At a minimum follow-up of 2 years after spacer placement, among patients who do not undergo the second stage revision (replacement of the spacer with a definitive prosthesis of the hip or knee): (1) What was the survival of the spacer free from unplanned reoperation or removal, the cumulative incidence of symptomatic infection, and the overall (Kaplan-Meier) survivorship of the patients? (2) What is the cumulative incidence of mechanical complications (spacer fracture or dislocation)? (3) What is the ambulatory status of patients who have retained their spacers? METHODS: Between March 2011 and July 2023, a total of 111 and 152 patients underwent first-stage revision with an articulating spacer placement as part of a planned two-stage procedure for chronic PJI after THA and TKA at our institution, respectively. Of these, 21% (23 of 111) in the THA group and 24% (37 of 152) in the TKA group did not undergo the anticipated second-stage reimplantation at our institution at least 1 year after spacer placement. Among the original cohorts, 2% (2 of 111) of patients who underwent THA and 3% (4 of 152) of patients who underwent TKA subsequently underwent second-stage reimplantation at outside institutions when reviewed, leaving 19% (21 of 111) in the THA group and 22% (33 of 152) in the TKA group with retained spacers. Of the original cohorts, 7% (8 of 111) in the THA group and 5% (8 of 152) in the TKA group did not have a 2-year follow-up, leaving 12% (13 of 111) of patients with THA and 16% (25 of 152) of patients with TKA available for analysis with a minimum of 2 years of follow-up or death in this retrospective study. The median (range) follow-up from spacer placement to the latest follow-up was 5 years (2 to 11) for patients with THA and 4 years (2 to 8) for patients with TKA. In the THA cohort, the median (range) age was 72 years (59 to 86), and eight patients were female; the median BMI was 32 kg/m 2 , and the median Charlson comorbidity index (CCI) was 3.5. In the TKA cohort, the median (range) age was 69 years (45 to 83), 13 patients were female, the median BMI was 31 kg/m 2 , and the median CCI was 4. Complication data following spacer placement were obtained from the electronic medical record and by telephone follow-up when needed. Clinical symptoms (swelling, erythema, warmth, fever, drainage, sinus tract, and pain), inflammatory markers (C-reactive protein and erythrocyte sedimentation rate), available radiographic findings, and laboratory test results (including synovial fluid analysis when obtained) were reviewed for evidence of infection or spacer-related mechanical failure. Infection after the spacer placement was defined as failure when the treating surgeon determined that an unplanned return to the operating room or spacer removal was warranted, acknowledging that postoperative evaluation thresholds varied among surgeons. Spacer-related mechanical failure was defined as spacer fracture or dislocation leading to reoperation or spacer removal. Patients were classified based on whether they underwent an unplanned reoperation or spacer removal. Patients who did not undergo unplanned reoperation or spacer removal were further categorized based on use of chronic suppressive antibiotics (decisions regarding chronic antibiotic therapy were made by the treating surgeon and/or infectious disease team). Patients who underwent reoperation were those who returned to the operating room because of concerning clinical, imaging, and/or laboratory findings of infection or mechanical complications, and the treating surgeon decided to proceed with revision surgery. All reoperation decisions were made by fellowship-trained arthroplasty surgeons with high-volume experience in two-stage revision. We used a competing-risks model to estimate survival of the spacer free from unplanned reoperation or removal attributable to infection or mechanical complications (calculated as 1 minus the corresponding cumulative incidence), with death treated as a competing event. Kaplan-Meier analysis was used to estimate patient survivorship, with death as the endpoint. Mortality data were obtained from medical records and hospital databases and were confirmed by telephone follow-up with family members and public records when needed. Ambulatory status before and after spacer placement was summarized descriptively and reported only for patients with both prespacer and postspacer data available (10 THAs and 25 TKAs); no formal hypothesis testing was performed for ambulatory or functional measures. RESULTS: At 2 years of follow-up, the survival of the spacer free from unplanned reoperation or removal was 89% (95% confidence interval [CI] 80% to 99%) for patients with THA and TKA combined, the cumulative incidence of infection was 5% (95% CI 0% to 12%), and the Kaplan-Meier survivorship of the patients was 92% (95% CI 84% to 100%). The cumulative incidence of mechanical complications (spacer fracture or dislocation) was 5% (95% CI 0% to 13%). In the THA cohort (10 patients), ambulatory status before the first stage included two patients using a wheelchair, two using a walker, one using crutches, two using a cane, and three walking without assistive devices. At latest follow-up, four patients used a wheelchair, two used a walker, two used a cane, and two walked without assistive devices. In the knee cohort (25 patients), ambulatory status before the first stage included two patients using a wheelchair, five using a walker, 13 using a cane, and five walking without assistive devices. At latest follow-up, two patients used a wheelchair, five used a walker, 13 used a cane, and five walked without assistive devices. CONCLUSION: Retained articulating spacers can provide infection control in selected patients who do not proceed to reimplantation after first-stage spacer placement for PJI. Although infection-free spacer survival is achievable, these patients remain at risk for mechanical complications, including dislocation and fracture, as well as progressive functional decline. These risks should be clearly discussed during preoperative counseling to align expectations and support informed decision-making. Further studies are needed to refine patient selection, improve spacer durability, and standardize definitions of treatment success in PJI. LEVEL OF EVIDENCE: Level III, case series.
引用
- Sarfraz A, Khury F, McCormick K, et al. What Is the Fate of Retained Antibiotic Spacers After First-stage Revision for Periprosthetic Joint Infection? Clin Orthop Relat Res. 2026. PMID: 41995314. doi:10.1097/CORR.0000000000003902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。